Cochlear hair cells lose NAD+ with age — preserving NAD+ may slow presbycusis.
This guide covers the underlying mechanism, the human and animal evidence supporting NMN and NAD+ precursor use for age-related hearing loss (presbycusis), a practical dosing protocol, and the products that consistently appear in evidence-based stacks.
NAD+ (nicotinamide adenine dinucleotide) is a redox coenzyme present in every cell. It powers mitochondrial ATP production via the electron-transport chain, fuels DNA-repair enzymes (PARPs), and is the obligatory substrate for sirtuins (SIRT1–SIRT7) — the enzyme family that controls gene expression, inflammation, and cellular survival.
NAD+ levels fall by 50% or more between ages 30 and 60. That decline is now considered a leading mechanistic explanation for age-related metabolic dysfunction, mitochondrial fatigue, accumulation of senescent cells, and the loss of muscle, skin, and cognitive resilience seen in aging.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two NAD+ precursors with the strongest human data. Both raise NAD+ via the salvage pathway: NR is phosphorylated by NRK1/NRK2 to form NMN, then converted to NAD+; NMN is dephosphorylated to NR for cellular uptake or — per Imai's lab — taken up directly through the Slc12a8 transporter in mouse small intestine. NADH is the reduced electron-carrying form. Niacinamide (nicotinamide) and niacin (nicotinic acid) are cheaper but raise NAD+ less efficiently, and high-dose nicotinamide (>1 g/day) inhibits sirtuins.
CD38, an NAD+-degrading enzyme, rises with age. Inhibitors of CD38 — apigenin, quercetin, luteolin — preserve the NAD+ you make. Methylation cofactors (TMG, B12, folate) become depleted with high-dose precursor use because the body methylates excess nicotinamide for excretion.
Mechanism specific to age-related hearing loss (presbycusis). Cochlear hair cells are post-mitotic and metabolically demanding. SIRT3-mediated mitochondrial protection is essential. Loss of NAD+ correlates with hair-cell dysfunction in aging.
Clinical evidence. Brown 2014 — NMN protected against noise-induced hearing loss in mice. Human prevention trials are not yet complete, but the mechanistic case is strong.
How NMN compares to other options for this condition. NMN is one component of a comprehensive approach. Lifestyle interventions (sleep, exercise, diet) typically produce the largest effect sizes. NMN amplifies but does not replace these foundations. NR is mechanistically equivalent and may be substituted.
Targeted protocol. 500 mg NMN AM + magnesium 400 mg (otoprotective) + hearing protection in noisy environments + annual audiometry after age 50.
Stack additions for this condition. TMG 500–1000 mg to support methylation; apigenin 50 mg PM to inhibit CD38; methylated B-complex if not already supplementing; magnesium glycinate PM for sleep architecture; omega-3 2–3 g for membrane and inflammation support.
Tracking. Subjective symptoms at 4 weeks; condition-specific objective markers at 8–12 weeks. Adjust dose if no response after 12 weeks of consistent use.
When to escalate. If oral NMN at 1000 mg/day for 12 weeks produces no measurable benefit, consider NAD+ IV/IM under medical supervision, switching precursor class, or adding a CD38 inhibitor.
Will NMN reverse existing hearing loss?
No. NMN is preventive, not regenerative for cochlear damage. Existing hearing loss requires audiology evaluation and may benefit from hearing aids.
How long until I notice effects on age-related hearing loss (presbycusis)?
Subjective changes typically begin at 4–8 weeks. Objective markers (lab values, physical performance, sleep architecture) usually take 8–12 weeks. Persistence is essential.
Can I combine NMN with my current treatment for age-related hearing loss (presbycusis)?
In most cases, yes — NMN has few documented interactions. Always disclose all supplements to your prescriber, particularly if you take medication for this condition.
What's the minimum effective dose of NMN for age-related hearing loss (presbycusis)?
Most NMN trials show benefit at 250–500 mg/day. Higher doses (1000 mg) may be needed for acute symptoms or when blood NAD+ testing shows suboptimal uplift.